Why is Medicamen Biotec falling/rising?

As of 15-Jul, Medicamen Biotech Ltd's stock is currently priced at 385.65, reflecting an increase of 1.8 (0.47%). Despite this slight uptick, the stock has recently underperformed, hitting a new 52-week low of Rs.376.7 today. Over the past week, the stock has declined by 4.10%, and it has shown a significant drop of 24.27% year-to-date. The company has a low Debt to Equity ratio, which is a positive factor; however, its operating profit has decreased at an annual rate of -16.39% over the last five years, contributing to a negative outlook. Furthermore, the stock's return on capital employed (ROCE) is low at 2.8, and it has consistently underperformed against benchmarks, generating a return of -18.46% over the past year.
In the broader market context, the Sensex has experienced a decline of 1.36% over the past week, which indicates that the stock's short-term performance is worse than the market average. While Medicamen Biotech's stock price has risen slightly today, it still lags behind the benchmark in terms of overall performance, particularly over longer periods. The stock's liquidity appears adequate, but the overall negative sentiment surrounding its long-term growth prospects and consistent underperformance against the benchmark suggests that any short-term gains may not be sustainable.